Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Chiroscience shares jump on trial results

Magnus Grimond
Tuesday 15 April 1997 18:02 EDT
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Chiroscience, the biotechnology group, saw its shares jump 14.5p to 380.5p yesterday after announcing the latest in a series of successful phase III trial results for its levobupivacaine long-acting local anaesthetic.

The Cambridge-based group said the tests, involving 60 women at St James's Hospital in Leeds, had shown the drug's efficacy was equivalent to theepidural anaesthetic used for childbirth, bupivacaine.

Chiroscience claims its product is a safer version of bupivacaine, which is made by Astra under the Marcaine brand and can cause side effects ranging from tingling to convulsions.

Analysts reacted favourably. Ian Smith of Lehman Brothers said the findings confirmed earlier trials and added weight to expectations that the drug would come to market. He put a value of 400p on the shares, before adding in last year's acquisition of Darwin, the US company backed by Bill Gates.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in